Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells

Alessandro Sgambato, Melania Dovizio, Thorsten J. Maier, Sara Alberti, Luigia Di Francesco, Emanuela Marcantoni, Gotz Munch, Constance M. John, Beatrix Suess, Dieter Steinhilber, Paola Patrignani

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

70 Citazioni (Scopus)

Abstract

Cyclooxygenase (COX)-2-derived prostanoids can influence several processes that are linked to carcinogenesis. We aimed to address the hypothesis that platelets contribute to aberrant COX-2 expression in HT29 colon carcinoma cells and to reveal the role of platelet-induced COX-2 on the expression of proteins involved in malignancy and marker genes of epithelial-mesenchymal transition (EMT). Human platelets cocultured with HT29 cells rapidly adhered to cancer cells and induced COX-2 mRNA expression, but not protein synthesis, which required the late release of platelet-derived growth factor and COX-2 mRNA stabilization. Platelet-induced COX-2-dependent prostaglandin E2 (PGE2) synthesis in HT29 cells was involved in the downregulation of p21(WAF1/CIP1) and the upregulation of cyclinB1 since these effects were prevented by rofecoxib (a selective COX-2 inhibitor) and rescued by exogenous PGE2. Galectin-3, which is highly expressed in HT29 cells, is unique among galectins because it contains a collagen-like domain. Thus, we studied the role of galectin-3 and platelet collagen receptors in platelet-induced COX-2 overexpression. Inhibitors of galectin-3 function (β-lactose, a dominant-negative form of galectin-3, Gal-3C, and anti-galectin-3 antibody M3/38) or collagen receptor-mediated platelet adhesion (revacept, a dimeric platelet collagen receptor GPVI-Fc) prevented aberrant COX-2 expression. Inhibition of platelet-cancer cell interaction by revacept was more effective than rofecoxib in preventing platelet-induced mRNA changes of EMT markers, suggesting that direct cell-cell contact and aberrant COX-2 expression synergistically induced gene expression modifications associated with EMT. In conclusion, our findings provide the rationale for testing blockers of collagen binding sites, such as revacept, and galectin-3 inhibitors in the prevention of colon cancer metastasis in animal models, followed by studies in patients.
Lingua originaleEnglish
pagine (da-a)25-40
Numero di pagine16
RivistaMolecular Pharmacology
Volume84
DOI
Stato di pubblicazionePubblicato - 2013

Keywords

  • Binding Sites
  • Blood Platelets
  • Cell Communication
  • Cell Line, Tumor
  • Colonic Neoplasms
  • Cyclin B1
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Dinoprostone
  • Down-Regulation
  • Epithelial-Mesenchymal Transition
  • Galectin 3
  • Gene Expression
  • Glycoproteins
  • HT29 Cells
  • Humans
  • Immunoglobulin Fc Fragments
  • Lactones
  • Lactose
  • Platelet-Derived Growth Factor
  • RNA, Messenger
  • Receptors, Collagen
  • Sulfones
  • Up-Regulation

Fingerprint

Entra nei temi di ricerca di 'Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells'. Insieme formano una fingerprint unica.

Cita questo